Clinical Trials Logo
  1. Home
  2. Agitation,Psychomotor
  3. NCT03110900

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation — loxapine  

Agitation,Psychomotor Clinical Trial

Official title:
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation

Clinical Trial Summary

The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

Clinical Trial Description

The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03110900
Study type Interventional
Source University of Arkansas
Contact
Status Terminated
Phase Phase 4
Start date September 30, 2017
Completion date April 4, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT05272501 - CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial N/A
Completed NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT06217146 - A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. N/A
Recruiting NCT05543681 - IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's Phase 2
Recruiting NCT03513549 - Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT05612711 - Dronabinol for Agitation in Dementia Crossover Trial Phase 2
Recruiting NCT04957238 - Physical Restraints in Intensive Care Unit Patients N/A
Completed NCT03208452 - The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation Phase 4
Terminated NCT03899506 - Olanzapine Versus Midazolam for Agitation
Completed NCT03211897 - Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation N/A
Recruiting NCT05783505 - A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use N/A
Completed NCT04053426 - Agitation Follow up After Introduction of a New Patient Care Algorithm
Completed NCT03226522 - Addressing Dementia Via Agitation-Centered Evaluation Phase 2/Phase 3
Recruiting NCT03926520 - Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) N/A
Recruiting NCT04075435 - Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia Early Phase 1
Completed NCT04276883 - Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Phase 3
Completed NCT04797715 - Assessing Clinical Outcomes in Alzheimer's Disease Agitation Phase 3
Completed NCT04251910 - Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Phase 1/Phase 2
Recruiting NCT05765162 - Safe Brain Initiative, Operationalizing Precision Anaesthesia